Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia

References

• National Comprehensive Cancer Network. Acute lymphoblastic leukemia (Version 2.2021). Available from: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf.
   Google Scholar
• Gökbuget N, Dombret H, Ribera JM, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524–1533.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032–2041.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–753.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Stelljes M, Advani AS, et al. Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leuk Lymphoma. 2020;61(8):2012–2015.
   PubMed Web of Science ®Google Scholar
• Dombret H, Topp MS, Schuh AC, et al. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(9):2214–2222.
   PubMed Web of Science ®Google Scholar
• Oriol A, Vives S, Hernández-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group. Haematologica. 2010;95(4):589–596.
   PubMed Web of Science ®Google Scholar
• Desjonquères A, Chevallier P, Thomas X, et al. Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study. Blood Cancer J. 2016;6(12):e504–e504.
   PubMedGoogle Scholar
• Sellar RS, Rowntree C, Vora AJ, et al. Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003. Br J Haematol. 2018;181(4):515–522.
   PubMed Web of Science ®Google Scholar
• Faderl S, Thomas DA, O'Brien S, et al. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011;11(1):54–59.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Pullarkat V, Patel R, et al. An effective reinduction regimen for first relapse of adult acute lymphoblastic leukemia. Med Oncol. 2013;30(4):744.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid Leukemia. J Clin Oncol. 2003;21(24):4642–4649.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Dombret H, Bassan R, et al. Inclusion and response criteria for clinical trials in relapsed/refractory acute lymphoblastic leukemia and usefulness of historical control trials. Haematologica. 2017;102(3):e118–e119.
   PubMed Web of Science ®Google Scholar
• D'Achille P, Seymour JF, Campbell LJ. Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature. Cancer Genet Cytogenet. 2006;171(1):52–56.
   PubMedGoogle Scholar
• Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the medical research council (MRC) UKALLXII/Eastern cooperative oncology group (ECOG) 2993 trial. Blood. 2007;109(8):3189–3197.
   PubMed Web of Science ®Google Scholar
• Goasguen JE, Dossot JM, Fardel O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood. 1993;81(9):2394–2398.
   PubMed Web of Science ®Google Scholar
• Damiani D, Michelutti A, Michieli M, et al. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. Br J Haematol. 2002;116(3):519–527.
   PubMed Web of Science ®Google Scholar
• Tafuri A, Gregorj C, Petrucci MT, et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood. 2002;100(3):974–981.
   PubMed Web of Science ®Google Scholar
• Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on Disease-Free survival in children, adolescents, and young adults with first relapse of B-Cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):833–842.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Pediatric acute lymphoblastic leukemia (Version 3.2021). Available from: https://www.nccn.org/professionals/physician_gls/pdf/ped_all.pdf.
   Google Scholar
• Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on Event-Free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325(9):843–854.
   PubMed Web of Science ®Google Scholar
• Blincyto. RED BOOK Online. IBM micromedex solutions. Ann Arbor, MI: Truven Health Analytics, Inc; [cited 2021 Aug 17]. Available from: http://www.micromedexsolutions.com
   Google Scholar
• Besponsa. RED BOOK Online. IBM micromedex solutions. Ann Arbor, MI: Truven Health Analytics, Inc; [cited 2021 Aug 17]. Available from: http://www.micromedexsolutions.com.
   Google Scholar
• Jabbour E, Sasaki K, Short NJ, et al. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021;127(12):2025–2038.
   PubMed Web of Science ®Google Scholar